The Challenge of Translating System Biology into Targeted Therapy of Cancer

Theoretical and Applied Aspects of Systems Biology - Computational Biology ◽

10.1007/978-3-319-74974-7_10 ◽

2018 ◽

pp. 175-194 ◽

Cited By ~ 1

Author(s):

Alessandra Jordano Conforte ◽

Milena Magalhães ◽

Tatiana Martins Tilli ◽

Fabricio Alves Barbosa da Silva ◽

Nicolas Carels

Keyword(s):

Targeted Therapy ◽

System Biology

Download Full-text

Targeted therapy: What are the targets?

Indian Journal of Neurotrauma ◽

10.1016/s0973-0508(05)80016-4 ◽

2005 ◽

Vol 2 (2) ◽

pp. 61-62 ◽

Cited By ~ 20

Author(s):

Peter Reilly

Keyword(s):

Targeted Therapy

Download Full-text

von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Yearbook of Oncology ◽

10.1016/s1040-1741(09)79299-1 ◽

2009 ◽

Vol 2009 ◽

pp. 97-98

Author(s):

M.S. Gordon

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Targeted Therapy ◽

Growth Factor ◽

Clear Cell ◽

Vascular Endothelial ◽

Cell Renal Cell Carcinoma ◽

Von Hippel Lindau ◽

Gene Status ◽

Endothelial Growth Factor

Download Full-text

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Seminars in Oncology ◽

10.1053/sonc.2002.35645 ◽

2002 ◽

Vol 29 (5 Suppl 14) ◽

pp. 31-37 ◽

Cited By ~ 80

Author(s):

Henry Q. Xiong ◽

James L. Abbruzzese

Keyword(s):

Pancreatic Cancer ◽

Epidermal Growth Factor Receptor ◽

Targeted Therapy ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Epidermal Growth

Download Full-text

Early reoccurrence of fetal ED-A+ Fibronectin and B+ Tenascin-C splicing variants after human cardiac transplantation: potential impact for targeted therapy of chronic rejection

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0034-1367306 ◽

2014 ◽

Vol 62 (S 01) ◽

Author(s):

M. Franz ◽

A. Berndt ◽

M. Matusiak-Brückner ◽

K. Grün ◽

H. Maschek ◽

...

Keyword(s):

Targeted Therapy ◽

Chronic Rejection ◽

Cardiac Transplantation ◽

Tenascin C ◽

Splicing Variants ◽

Potential Impact

Download Full-text

Lungenkarzinom: Genomisch stratefiziert behandeln: Wohin geht die Entwicklung?

Onkologische Welt ◽

10.1055/s-0038-1630213 ◽

2012 ◽

Vol 03 (04) ◽

pp. 184-185

Author(s):

Christine Vetter

Keyword(s):

Targeted Therapy

Die „Targeted Therapy” hat in den vergangenen Jahren in vielen Bereichen der Onkologie Fuß gefasst und gewinnt auch beim Lungenkarzinom zunehmend an Boden. Wie sich diese neue Therapierichtung künftig entwickeln kann, war eines der Themen beim diesjährigen Deutschen Krebskongress in Berlin.

Download Full-text

From molecular diagnostics to molecular targeted therapy with natural product small molecule inhibitors in oral squamous cell carcinoma

Planta Medica ◽

10.1055/s-2007-986722 ◽

2007 ◽

Vol 73 (09) ◽

Cited By ~ 1

Author(s):

VB Konkimalla ◽

VL Suhas ◽

NR Chandra ◽

E Gebhart ◽

T Efferth

Keyword(s):

Squamous Cell Carcinoma ◽

Targeted Therapy ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Natural Product ◽

Molecular Diagnostics ◽

Small Molecule ◽

Squamous Cell ◽

Molecular Targeted Therapy ◽

Small Molecule Inhibitors

Download Full-text

NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer

Experimental Oncology ◽

10.32471/exp-oncology.2312-8852.vol-42-no-4.15414 ◽

2020 ◽

Keyword(s):

Targeted Therapy ◽

Prognostic Marker

Download Full-text

Atopic dermatitis: new horizons of therapy

Medical alphabet ◽

10.33667/2078-5631-2019-1-7(382)-29-32 ◽

2019 ◽

Vol 1 (7) ◽

pp. 29-32 ◽

Cited By ~ 4

Author(s):

L. S. Kruglova ◽

E. M. Gensler

Keyword(s):

Blood Pressure ◽

Immune Response ◽

Allergic Rhinitis ◽

Atopic Dermatitis ◽

Targeted Therapy ◽

Inflammatory Response ◽

Bronchial Asthma ◽

New Horizons ◽

The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Download Full-text